期刊文献+

豚鼠动物模型评价牛口蹄疫Asia-1型灭活疫苗效力的研究 被引量:1

Evaluation on the potency of inactivated vaccine against foot-and-mouth disease virus Asia 1 from cattle using guinea pigs as animal model
原文传递
导出
摘要 以豚鼠为试验动物模型,探索一种应用豚鼠替代牛进行牛口蹄疫Asia-1型灭活疫苗效力检验的方法。豚鼠和牛同步对6批牛口蹄疫Asia-1型灭活疫苗进行PD50效力检验,其中2批进行重复性试验。豚鼠分别在免疫后7、14、21和28天采血检测Asia-1型的中和抗体水平。统计学分析显示,测定的豚鼠PD50和牛PD50之间具有极显著的相关性(R=0.846,P<0.01);经回归分析,建立了应用豚鼠测定的PD50预测牛口蹄疫Asia-1型灭活疫苗效力的线性回归模型(y=1.625x-0.704;x表示豚鼠PD50结果;y表示牛PD50结果)。F检验(F=15.058,P=0.008)和t检验(t=3.880,P=0.008)证明该线性方程成立。豚鼠的Asia-1型抗体水平随免疫剂量的增加而升高,攻毒时的抗体水平与攻毒后的保护力存在正相关关系。本研究初步证明,在未来的效力检验中豚鼠可作为试验动物替代牛进行口蹄疫Asia-1型灭活疫苗效力检验。 Guinea pig was used as an animal model to evaluate the potency of inactivated vaccine against foot-and-mouth disease virus (FMDV) Asia 1 from cattle. Six batches of inactivated vaccines were tested for their 50% protective dose (PDso) using guinea pigs and cat- tie at the same time. Among the six batches, two batches were repeatedly tested. Guinea pigs were bled at days 7, 14, 21 and 28 post-vacci- nation, serum samples were used to determine the virus neutralizing antibody titers against serotype Asia-1 FMDV. Statistical analysis of the results demonstrated a very significant correlation of PDs0 value of inactivated bovine serotype Asia-1 FMD vaccines between tests in guinea pigs and in cattle ( R=0. 846, P〈0. 01 ). A linear regression model y1. 625x-0. 704, where x is PD50 in guinea pigs and y is PD50 in cattle, was created for the prediction of potency of inactivated bovine serotype Aaia-1 FMD vaccines using PDs0 value obtained in guinea pigs. Furthermore, the model was strongly supported and approved by F test (F = 15. 058, P= 0. 008) and T test (t = 3. 880, P = 0. 008 ). Anti- body titers against serotype Aisa-1 FMDV in inoculated guinea pigs increased as the increasing of immunizing dose. There was a positive cor- relation between antibody titers in guinea pigs at challenge and the protection of the guinea pigs from the FMDV challenge. This initial study revealed that guinea pig can be used to replace cattle as the laboratory animal for the needed potency tests of inactivated bovine serotype Asia-1 FMD vaccines in future.
出处 《畜牧与兽医》 北大核心 2011年第9期7-12,12,共6页 Animal Husbandry & Veterinary Medicine
基金 "863"计划--"新型重大动物疫病疫苗与诊断试剂创制及生产工艺创新"(2011AA10A213)
关键词 口蹄疫灭活疫苗 Asia-1型 效力试验 豚鼠 inactivated foot-and-mouth disease vaccine serotype Asia-1 potency test guinea pig
  • 相关文献

参考文献15

  • 1Council of Europe, Directorate for the Quality of Medicines. Foot- mid-mouth disease (ruminants) vaccine (inactivated) //EuropeanPharmacopoeia 5th Edition-Supplement 5.1 [ M ]. Paris: Renouf Publishing Co. Ltd, 2005 : 2860-2861.
  • 2World Organization for Animal Health (OIE). Chapter 2. 1.1 : Foot and mouth disease. In : Manual of Diagnostic Tests and Vaccines for Terrestrial Animals [ EB/OL]. [ 2010-10-20 ] http://www, oie. int/esp/normes/sauv% 2018% 2007% 202005/ normes/mmanual/A 00024. htm.
  • 3Barnett P V, Statham R J, Vosloo W, et al. Foot-and-mouth disease vaccine potency testing: determination and statistical validation of a model using a serological approach [J]. Vaccine, 2003, 21 (23) : 3240-3248.
  • 4Goris N, Willems T, Diev V I, et al. Indirect foot-and-mouth disease vaccine potency testing based on a serological alternative [ J]. Vaccine, 2008, 26: 3870-3879.
  • 5Robiolo B, Torre J L, Maradei E, et al. Confidence in indirect as- sessment of foot-and-mouth disease vaccine potency and vaccine matching carried out by liquid phase ELISA and virus neutralization tests [ J]. Vaccine, 2010, doi:10. 1016/j. vaccine. 2010.07. 012.
  • 6Gofis N, de Clercq K. Quality assurance/quality control of foot and mouth disease solid phase competition enzyme-linked immunosorbent assay. Patt 1, Quality assurance: development of secondary and working standards [ J]. Revue Scientifique et Technique - Office In- ternational des Epizooties, 2005, 24(3): 995-1004.
  • 7Waldmann O, Pape J. Die Kuenstliche Uebertragung der Maul- und Klauenseuche auf das Meerschweinchen [ J ]. Berl MUnch Tieruarztl Wschr, 1920, 36: 519-520.
  • 8Hemiman K A J, Sellers R F. Protection of guinea-pigs against foot- and-mouth disease by simultaneous inoculation of sendal virus and inactivated foot-and-mouth disease vaccine [ J ]. Archives of Virolo- gy, 1972, 37: 97-103.
  • 9Eissner G, Bohm H O. Efficacy testing of anti-foot-and-mouth disease vaccines in guinea pigs using mytotropic strains [ J ]. Develop- ments in Biological Standardization, 1976, 35 : 279-283.
  • 10Terpstra C, Frenkel S, Strayer P J, et al. Comparison of laboratory techniques for the evaluation of the antigenic potency of foot-and- mouth disease virus cultures and vaccines [ J]. Veterinary Microbiology, 1976, 1(1) : 71-83.

二级参考文献20

  • 1European Pharmacopoeia-Commisslon. European Pharmacopoeia 5.5 ed : Foot-and-mouth disease (ruminants) vaccine ( inactivated) [M]. Paris: PaBalogh Scientific Books, 2006 : 875-876.
  • 2Bergmann I E. The role of reference laboratories in animal health programmes in South America[J]. Rev Sci Tech, 2003, 22(2) :537-545.
  • 3Cox S J, Voyce C, Parida S, et al. Further evaluation of higher potency vaccines for early protection of cattle against FMDV direct contact challenge[J]. Vaccine,2007, 25(44):7687-7695.
  • 4Cox S J, Voyce C, Parida S, et al. Effect of emergency FMD vaccine antigen payload on protection, sub-clinical infection and persistence following direct contact challenge of cattle[J]. Vaccine, 2006, 24(16) :3184-90.
  • 5Cox S J, Voyce C, Parida S, et al. Protection against directcontact challenge following emergency FMD vaccination of cattle and effect on virus excretion from the oropharynx[J]. Vaccine, 2005, 23(9) :1106-13.
  • 6Orsel K, de Jong M C, Bouma A, et al. The effect of vaccination on foot and mouth disease virus transmission among dairy cows[J].Vaccine, 2007,25(2) :327-335.
  • 7Karber G. Beitragzur kollektiven Behandlung pharmakologischer Reihenversuche[J].Arch Exp Pathol Pharmak, 1931, (162) : 480-487.
  • 8Doel T. Potency testing of foot-and-mouth disease vaccines: an industrial perspective[A], in : Proceedings of international symposium organised by the European directorate for the quality of medicines[C]. Strasbourg France:EDQM,2003:41-47.
  • 9Goris N,Merkelbach P P, Diev V I,et al. European Pharmacopoeia foot-and-mouth disease vaccine potency testing in cattle: between test variability and its consequences [J]. Vaccine, 2007, 25(17): 3373-3379.
  • 10Hecke F, Uhlmann W, Lorenz R. Bericht uber die ergebnisse der grossversuchs 1957-1958 zur wirkaamkeitsprufung der Maulund klavenseuche-koncentratvakzine nach pyl unf der originalvakzine nach waldmann und kobe[J].Beziehung Zwischen Serumneutralisation und Immunitat, 1960,12 : 1-11.

共引文献1

同被引文献5

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部